Athira Pharma, Inc. financial data

Symbol
ATHA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
18706 North Creek Parkway, Suite 104, Bothell, Washington
Fiscal year end
December 31
Former names
M3 Biotechnology, Inc. (to 1/23/2019)
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 517 % -53.7%
Debt-to-equity 24.1 % +171%
Return On Equity -95.5 % -98.1%
Return On Assets -77 % -73.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.4M shares +1.01%
Common Stock, Shares, Outstanding 38.4M shares +1.01%
Entity Public Float 96.3M USD -2.73%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 38.4M shares +1%
Weighted Average Number of Shares Outstanding, Diluted 38.4M shares +1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 94.3M USD +25.5%
General and Administrative Expense 27.1M USD -18.7%
Costs and Expenses 120M USD +1.1%
Operating Income (Loss) -120M USD -1.1%
Nonoperating Income (Expense) 1.75M USD +468%
Net Income (Loss) Attributable to Parent -113M USD -5.3%
Earnings Per Share, Basic -2.97 USD/shares -4.95%
Earnings Per Share, Diluted -2.97 USD/shares -4.95%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 73.8M USD -35%
Assets, Current 107M USD -44.5%
Property, Plant and Equipment, Net 2.93M USD -23.8%
Operating Lease, Right-of-Use Asset 933K USD -19.5%
Other Assets, Noncurrent 55K USD -9.84%
Assets 111M USD -46.5%
Accounts Payable, Current 475K USD -22.4%
Employee-related Liabilities, Current 2.87M USD +7.89%
Accrued Liabilities, Current 16M USD +49.8%
Liabilities, Current 26.9M USD +24.2%
Operating Lease, Liability, Noncurrent 1.02M USD -27.8%
Liabilities 27.9M USD +21%
Accumulated Other Comprehensive Income (Loss), Net of Tax -38K USD +96%
Retained Earnings (Accumulated Deficit) -362M USD -45.6%
Stockholders' Equity Attributable to Parent 83.3M USD -54.9%
Liabilities and Equity 111M USD -46.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.8M USD +1.49%
Net Cash Provided by (Used in) Financing Activities 99K USD -52.9%
Net Cash Provided by (Used in) Investing Activities 13M USD -63.3%
Common Stock, Shares Authorized 900M shares 0%
Common Stock, Shares, Issued 38.4M shares +1.01%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.8M USD -235%
Deferred Tax Assets, Valuation Allowance 71.2M USD +65.7%
Deferred Tax Assets, Gross 71.8M USD +63%
Operating Lease, Liability 1.41M USD -19.8%
Depreciation 973K USD +2.42%
Payments to Acquire Property, Plant, and Equipment 5K USD -97.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -113M USD -5.43%
Lessee, Operating Lease, Liability, to be Paid 1.59M USD -22.9%
Property, Plant and Equipment, Gross 5.74M USD +0.77%
Operating Lease, Liability, Current 391K USD +12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 509K USD +3.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 494K USD +2.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 185K USD -40.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 509K USD +3.04%
Deferred Tax Assets, Operating Loss Carryforwards 31.3M USD +30.1%
Unrecognized Tax Benefits 3.11M USD +121%
Deferred Tax Assets, Net of Valuation Allowance 25.2M USD +136%
Share-based Payment Arrangement, Expense 10.6M USD -0.7%
Interest Expense 2K USD